CV Emilio Alba

• 

  Emilio Alba Conejo
  

  Catedrático de Universidad

  Tel: 952131615     E-mail: ealbac@uma.es

  Despacho: Facultad de Medicina. Primera planta

• Emilio ALBA  is Director of Medical Oncology Intercenter Unit of Regional and Virgen de la Victoria University Hospitals of Málaga, and group leader of “Clinical and Translational Research on Cancer”. His has ample experience and competence as a reputed clinical researcher in breast cancer and in particular in the field of biomarkers of response. He is co-author of more than 180 publications in high impact international journals and researcher of several Projects of competitive public and private calls, as well as co-inventor of  patents in the field of biomarkers in breast cancer.
• Dr. Alba is currently Full Professor of Oncology at the University of Malaga, Coordinator of the Scientific Area of Onco-Hematology-Rare Diseases, at the Institute of Biomedical Research in Malaga (IBIMA), and Director of the Center for Medical-Health Research, CIMES-University of Malaga. Currently, he is the PI of the CIBERonc Breast Cancer CB16/12/00481.
• He belongs to the GEICAM, Spanish Breast Cancer Group, Scientific Committee and have participated as investigator of this group from its foundation on 1995. Currently member of the Real Academia de Medicina de Andalucía Oriental (from 2013). Member of IBIMA Scientific Committee and the Permanent Assessment Commision for this institution. Member of ANECA experts panel for the teacher’s evaluation (from 2011). Assessor of the Agencia Estatal de Investigación from 2017. SAS expert in second oncology opinion (from 2004).
• It is also important his relevant role in different types of Oncology Commissions of Trust such as the National Medical Oncology Commission, representing the SEOM (2007-11), Vice-President  and President (2009-11) of SEOM. Dr Alba has participated in the ESMO-ASCO Commission for the design of a curriculum in Medical Oncology, the Steering Committee of the IMELDA for the design of clinical trials, and the board of GEICAM-Spanish Group for the Investigation and Treatment of Breast Cancer.